Holen Sie sich die Stockscreener-App
21.94
1.29%
0.28
Schlusskurs vom Vortag:
$21.66
Offen:
$20.89
24-Stunden-Volumen:
113.99K
Relative Volume:
0.53
Marktkapitalisierung:
$312.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.19%
1M Leistung:
+23.54%
6M Leistung:
+37.55%
1J Leistung:
-49.35%
1-Tages-Spanne:
$20.80
$22.22
1-Wochen-Bereich:
$20.80
$23.50
52-Wochen-Spanne:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.94 | 306.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Craig Hallum | Buy |
| 2025-05-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Is Neurogene Inc. a good long term investmentRobust investment performance - jammulinksnews.com
Neurogene Inc. Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
What makes Neurogene Inc. stock price move sharplyReal Time Stock Signal - Newser
What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com
What drives Neurogene Inc. stock priceSuperior stock selection - jammulinksnews.com
how neurogene inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
How Neurogene Inc. stock performs during market volatilityHigh Return Conservative Stocks - Newser
Why Neurogene Inc. stock attracts strong analyst attentionFree Investment Community - Newser
Neurogene announces inducement grants - Medical Buyer
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Neurogene jumps as FDA approves rare gene therapy trial design - TradingView
Stifel reiterates Buy rating on Neurogene stock, backs pivotal trial design - Investing.com
FDA approves Neurogene’s Rett syndrome gene therapy registrational trial design - Investing.com
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
Neurogene Inc.(NasdaqGM: NGNE) dropped from Russell 3000E Growth Index - MarketScreener
Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance
Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World
Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus
Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria
BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World
Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus
Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks
Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada
Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World
Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks
Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):